Gedeon Richter PLC (RGEDF)
ValueMarkers Composite Index
100% below intrinsic value ($61)
Gedeon Richter PLC (RGEDF) — VMCI valuation read
RGEDF prints VMCI 71/100 inside the Healthcare sector, where the median sits at 50. The 21-point above-median delta is the cleanest single-number summary of Gedeon Richter PLC's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On RGEDF, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** RGEDF trades at 14.0x earnings, 22% below the Healthcare median of 18.0x; that is the value line. ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 0.6x leaves covenant headroom; that is the risk line for Gedeon Richter PLC on the trailing financials.
RGEDF rose 0.8% over the trailing 7 days, with a -14.8% read on a 30-day basis.
Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. It operates through the following segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceutical segment engages in research and development, manufacturing, sales and marketing of pharmaceutical products. The Wholesale & Retail segment represents the distribution of companies and pharmacies that are part of the sales network in various regional markets and, as such, convey its products to consumers. The Other segment relates to the business of the members of the group that provide marketing and sales support services. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.